- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01245426
A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)
November 30, 2016 updated by: GlaxoSmithKline
A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to Determine the Efficacy and Dose Response of Repeat Inhaled Doses of GW870086X on FEV1 in Adults With Persistent Asthma
This is a randomised, double-blind, placebo-controlled, parallel group study to determine the efficacy of twenty-seven day- repeat inhaled daily doses of GW870086X on forced expiratory volume in 1 second (FEV1).
Initially there will be 3 treatment arms; placebo, 2mg GW870086X and 4mg GW870086X.
After an interim analysis the trial may; continue to completion using the original doses, be terminated early, or have a fourth arm added of either 1mg GW870086X once daily or 3mg GW870086X once daily.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomised, double-blind, placebo-controlled, parallel group study to determine the efficacy of twenty-seven day- repeat inhaled doses of GW870086X on FEV1.
GW870086X is a novel inhaled corticosteroid with potent glucocorticoid activity currently in development by GlaxoSmithKline (GSK) as an inhaled treatment of persistent asthma.
Initially, subjects will be randomised to receive placebo, 2mg or 4mg GW870086X once daily.
An interim analysis will be performed on the primary endpoint to potentially adapt the study design after approximately 45 subjects have completed dosing.
Based on the results of the interim analysis, the trial may continue to completion using the original doses or an adaptation to the doses could be made.
Either the 1mg GW870086X once daily arm or 3mg GW870086X once daily arm may be added, or the trial could be terminated early.
After screening there will be a 4 week run in period prior to start of treatment and after will be a follow up period 1-2 weeks after last dose.
Approximately 120 subjects will complete the study.
Key safety assessments include; clinical laboratory tests, vital signs and collection of adverse events (AE's).
Study Type
Interventional
Enrollment (Actual)
136
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sofia, Bulgaria, 1612
- GSK Investigational Site
-
-
-
-
-
Berlin, Germany, 14050
- GSK Investigational Site
-
Berlin, Germany, 10969
- GSK Investigational Site
-
Hamburg, Germany, 20354
- GSK Investigational Site
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60596
- GSK Investigational Site
-
-
Niedersachsen
-
Hannover, Niedersachsen, Germany, 30625
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Magdeburg, Sachsen-Anhalt, Germany, 39112
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Luebeck, Schleswig-Holstein, Germany, 23552
- GSK Investigational Site
-
-
-
-
-
Bloemfontein,, South Africa, 9301
- GSK Investigational Site
-
George, South Africa, 6529
- GSK Investigational Site
-
Newton Park, Port Elizabeth, South Africa, 6045
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female between 18 and 65 years
- A female subject is eligible to participate if she is of: Non-childbearing potential. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment.
- Male subjects must agree to use one of the protocol contraception methods.
- Body weight, men ≥ 50 kg, women ≥ 45 kg and BMI within the range 18.5 - 29.0 kg/m2 (inclusive).
- Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta-2 agonist therapy
- Severity of Disease: A best FEV1 of 60%-85% of the predicted normal value during the Visit 1 screening period.
- No history of smoking within 6 months of the start of the study and with a total pack year history of ≤10 pack years
- Capable of giving written informed consent
- Single QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
- AST and ALT < 2xULN; alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
Exclusion Criteria:
- A positive test for Hepatitis B or Hepatitis C antibody.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities
- The subject has a positive pre-study drug/alcohol screen unless a positive can be explained by the patients' medication.
- Past or present disease, which as judged by the investigator, may affect the outcome of this study.
- Clinically significant abnormalities in safety laboratory analysis at screening, as determined by the investigator.
- Subject is hypertensive at screening.
- History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures.
- Administration of oral, injectable or dermal steroids within 8 weeks of screening.
- Exacerbation of asthma within 4 weeks prior to the first dose of study medication.
- Respiratory Infection that is not resolved within the 4 weeks before screening and led to a change in asthma management, or in the opinion of the Investigator is expected to affect the subjects asthma status or the subjects ability to participate in the study.
- Any asthma exacerbation requiring oral corticosteroids within 8 weeks of screening. A subject must not have had any hospitalisation for asthma within 6 months prior to screening
- A positive test for HIV antibody.
- History of regular alcohol consumption within 6 months of the study.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Use of prescription or non-prescription drugs within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. Paracetamol is an exception and will be permitted at daily doses of up to 4 g from screening to follow-up.
- Has taken Xanthines (including theophylline, but not including caffeine), anticholinergics, cromoglycates and/or long-acting beta-2 agonists within 1 week prior to screening and is unable to abstain from them throughout the study.
- Unable to abstain from other medications other than short acting inhaled beta-2 agonists and paracetamol (up to 4 g per day) 7 days before screening until the follow-up visit.
- Unable to abstain from medication or supplements that significantly inhibit the cytochrome P450 subfamily enzyme CYP3A4, from screening and throughout the study.
- Unable to use the DISKHALER® device correctly.
- History of sensitivity to any of the study medications.
- Where participation in the study would result in donation of blood or blood products in excess of 500 ml within a 56 day period.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- The subject is not able to understand or comply with protocol requirements, instructions and protocol stated restrictions.
- Vulnerable subjects.
- Subject is mentally or legally incapacitated.
- Urinary cotinine levels indicative of smoking or history within 6 months prior to screening.
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GW870086 2mg
GW870086 2mg once daily in the morning for 27 ± 2 days
|
oral inhalation
|
Experimental: GW870086 4mg
GW870086 4mg once daily in the morning for 27 ± 2 days
|
oral inhalation
|
Placebo Comparator: Placebo
Placebo once daily in the morning for 27 ± 2 days
|
oral inhalation
|
Experimental: GW870086 1mg
GW870086 1mg once daily in the morning for 27 ± 2 days
|
oral inhalation
|
Experimental: GW870086 3mg
GW870086 3mg once daily in the morning for 27 ± 2 days
|
oral inhalation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline associated with GW870086X versus placebo at Day 28 on FEV1
Time Frame: Day 28
|
Day 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in FEV1 on Day 7, Day 14 and Day 21
Time Frame: Days; 7, 14, 21
|
Days; 7, 14, 21
|
Change from baseline in peak expiratory flow rate (PEFR) measured twice daily over 28 days
Time Frame: Days 1-28
|
Days 1-28
|
Rescue medication usage
Time Frame: Days 1-28
|
Days 1-28
|
Assessment of vital signs, safety laboratory parameters and incidences of adverse events throughout treatment period
Time Frame: 9-10 weeks
|
9-10 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
July 1, 2011
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
November 19, 2010
First Submitted That Met QC Criteria
November 19, 2010
First Posted (Estimate)
November 22, 2010
Study Record Updates
Last Update Posted (Estimate)
December 1, 2016
Last Update Submitted That Met QC Criteria
November 30, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 114749
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Statistical Analysis Plan
Information identifier: 114749Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 114749Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 114749Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 114749Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 114749Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 114749Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 114749Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on GW870086 2mg
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Cascade Pharmaceuticals, IncRecruitingPrimary Biliary Cholangitis (PBC)China
-
Cascade Pharmaceuticals, IncRecruitingPrimary Sclerosing CholangitisChina
-
Boryung Pharmaceutical Co., LtdCompletedSmoking CessationKorea, Republic of
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.Completed
-
Abalonex, LLCNot yet recruitingTraumatic Brain Injury | Cerebral Edema
-
Rigel PharmaceuticalsCompletedAsthmaUnited States, Canada
-
Zydus Therapeutics Inc.CompletedNon Alcoholic SteatohepatitisUnited States